The FY24 ASUDRP CA supports the establishment of a Consortium whose purpose is to identify, evaluate, and advance pharmacotherapies for alcohol, opioid, and other substance use disorders, with an emphasis on other co-occurring mental health conditions, through rigorous, collaborative research efforts that translate basic knowledge and early-stage clinical products into evidence-based treatments. The goal of this research is to maximize functioning and quality of life for Service Members, their Families, Veterans, and the American public.
Each individual organization must apply to this program announcement as a Consortium Management Core (CMC) by means of a single application, and may also serve as a future research and/or trial site. The CMC will be responsible for coordinating with the Consortium Steering Committee (CSC) and Consortium Executive Committee (CEC) to prioritize, propose, conduct, and analyze basic research and clinical trials, and developing a roadmap to translate basic science knowledge into evidence-based treatments for ASUD. Clinical trials that include military and Veteran populations are encouraged.
Deadlines:
• Required Pre-Application Submission Deadline: Sep. 10, 2024
• Application Submission Deadline: Sep. 24, 2024
To meet the intent of the funding opportunity, the Consortium is required to align proposed research to the FY24 ASUDRP focus areas which are aimed at treating alcohol and other substance use disorders and improving treatment adherence, preventing relapse, and reducing risk of misuse. The population of interest includes individuals with alcohol and other substance use disorders, including opioid use disorder, particularly when co-occurring with posttraumatic stress disorder (PTSD), traumatic brain injury (TBI), and/or other mental health conditions. The FY24 ASUDRP focus areas are:
• New medication targets
• Novel medications
• Repurposed medications
• Vaccines and other immunotherapies
• Drug-drug combinations
• More potent, longer-acting formulations to counteract opioid (including fentanyl and its analogs) overdose
Independent intramural (DOD) and extramural investigators at all academic levels (or equivalent) are eligible to submit applications. The CMC PI must have at least a 51% appointment at the CMC’s institution.
An investigator may be named as a CMC PI on only one FY24 ASUDRP CA application.
The anticipated total costs budgeted for the entire period of performance for an FY24 ASUDRP CA should not exceed $11.525M, of which only $3.525M is currently available. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.